Neurophysin I: a reliable, novel, and robust biomarker for oxytocin

What Was Tested

Researchers studied Oxytocin in this randomized controlled trial publication.

However, diagnosis and clinical progress have been hindered by challenges in reliably measuring OXT.

Who Took Part

The abstract describes 15 patients taking part.

By PubMed's age tags, the people studied were young adults, adults and middle-aged adults, both men and women.

Analysis of a double-blind, placebo-controlled, cross-over study including 15 patients with hypothalamic-posterior-pituitary dysfunction and 15 healthy controls matched according to age (±3), sex, body mass index (±2), and menopause/hormonal contraceptives.

Subjective drug effects were assessed using visual analog scales ranging from 0 = "not at all" to 100 = "extremely," or were bidirectionally ranging from -50 to +50 mm, with 0 being the neutral measure = "no effect." The primary endpoint-net incremental area under the curve (AUC) of NP-I from 0 to 300 min-was analyzed using a linear mixed-effects model.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and crossover study.

The patients were allocated by chance, so the Oxytocin group and the comparison group should start out alike.

Neither the patients nor the staff measuring them knew who was on Oxytocin, so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Oxytocin group a baseline to be compared against.

In the crossover set-up each of the patients took both Oxytocin and the comparison in turn, acting as their own control.

NP-I and OXT levels were measured at 6 time points over 5 h after drug intake.

What Was Measured

However, diagnosis and clinical progress have been hindered by challenges in reliably measuring OXT.

Topics PubMed links to this paper include Biomarkers, N-Methyl-3,4-methylenedioxyamphetamine, Neurophysins, Oxytocin and Case-Control Studies.

Author keywords: AVP, AVP deficiency, MDMA, copeptin, diagnostic and hypopituitarism.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Oxytocin in 15 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2025 (European journal of endocrinology), a journal based in England.

More context: the Oxytocin compound page, all human trials.